Tyrosine Protein Kinase ITKTSK – Pipeline Review, H2 2019

“Global Markets Direct’s, ‘Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2)- Pipeline Review, H2 2019’, provides in depth analysis on Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Immunology, Dermatology, Gastrointestinal, Oncology and Genetic Disorders under development targeting Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.”

Scope


– The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2)

– The report reviews Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects

– The report assesses Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) targeted therapeutics”

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

“Aclaris Therapeutics Inc

Arrien Pharmaceuticals LLC

Corvus Pharmaceuticals Inc

Daewoong Pharmaceutical Co Ltd

Japan Tobacco Inc

Novartis AG

Principia Biopharma Inc”

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC

2.7.10.2) Overview

Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC

2.7.10.2) Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC

2.7.10.2) Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC

2.7.10.2) Companies Involved in Therapeutics Development

Aclaris Therapeutics Inc

Arrien Pharmaceuticals LLC

Corvus Pharmaceuticals Inc

Genentech Inc

Japan Tobacco Inc

Novartis AG

Principia Biopharma Inc

Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC

2.7.10.2) Drug Profiles

ARN-4079 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GNE-4997 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JTE-051 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pazopanib hydrochloride Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pazopanib hydrochloride + pembrolizumab Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PRN-694 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit ITK and TXK for Psoriasis and Oncology Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit ITK for Autoimmune Disorders, Chronic Inflammation and Colorectal Cancer Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit ITK for Oncology Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC

2.7.10.2) Dormant Products

Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC

2.7.10.2) Discontinued Products

Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC

2.7.10.2) Product Development Milestones

Featured News & Press Releases

Jul 21, 2016: Mateon Announces Enrollment of First Patient in Phase 2 Portion of PAZOFOS Study in Recurrent Ovarian Cancer

Mar 16, 2015: Cancer drug may reduce bleeding in patients with rare genetic disorder, HHT

Sep 01, 2014: Arrien Pharmaceuticals Provides Update on ARN-4079

Apr 01, 2014: Results from phase III patient preference study of GSK’s Votrient (pazopanib) vs. Sutent (sunitinib) in advanced renal cell carcinoma published in Journal of Clinical Oncology

Mar 31, 2014: Votrient as maintenance therapy for advanced ovarian cancer in the EU

Aug 21, 2013: Pazopanib shows better quality-of-life in advanced kidney cancer

Aug 07, 2013: GSK seeks additional indication approval for Votrient from EMA

Jul 11, 2013: GlaxoSmithKline's cancer drug Votrient receives full EU approval

Jun 01, 2013: GSK's Votrient Meets Primary Endpoint In Phase III Clinical Trial As Maintenance Therapy In Women With Advanced Epithelial Ovarian Cancer

Jan 08, 2013: Combination Of Pazopanib And Paclitaxel May Slow Anaplastic Thyroid Cancer, Mayo Clinic Study Shows

Oct 01, 2012: GlaxoSmithKline's Votrient Meets Primary Endpoint In Pivotal Phase III Study Of Advanced Renal Cell Carcinoma

Aug 07, 2012: GlaxoSmithKline Receives Marketing Authorization From European Commission For Pazopanib

May 25, 2012: GSK Receives Positive Opinion from European CHMP For Pazopanib In Treatment Of Patients With Certain Advanced Soft Tissue Sarcomas

Apr 26, 2012: GSK's Votrient Receives FDA Approval For Treatment Of Advanced Soft Tissue Sarcoma

Mar 20, 2012: GSK Announces Positive Vote From FDA Panel For Pazopanib In Certain Advanced Soft Tissue Sarcomas

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

“List of Tables

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Indications, H2 2019

Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019

Number of Products under Development by Indications, H2 2019 (Contd..2), H2 2019

Number of Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Products under Development by Companies, H2 2019 (Contd..2), H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Pipeline by Aclaris Therapeutics Inc, H2 2019

Pipeline by Arrien Pharmaceuticals LLC, H2 2019

Pipeline by Corvus Pharmaceuticals Inc, H2 2019

Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2019

Pipeline by Japan Tobacco Inc, H2 2019

Pipeline by Novartis AG, H2 2019

Pipeline by Principia Biopharma Inc, H2 2019

Dormant Products, H2 2019

Dormant Products, H2 2019 (Contd..1), H2 2019

Discontinued Products, H2 2019”

List of Figures

“List of Figures

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Top 10 Indications, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019”

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports